Ginkgo Bioworks Holdings (DNA)

Currency in USD
8.930
-1.390(-13.47%)
Closed·
9.250+0.320(+3.58%)
·
DNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.3509.544
52 wk Range
5.37017.580
Key Statistics
Prev. Close
10.32
Open
8.65
Day's Range
8.35-9.544
52 wk Range
5.37-17.58
Volume
2.21M
Average Volume (3m)
1.23M
1-Year Change
15.0773%
Book Value / Share
8.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.500
Downside
-4.82%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Ginkgo Bioworks Holdings News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
0 Hold
2 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 8.500
(-4.82% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Sell5.00-44.01%9.00MaintainMar 12, 2026
BTIG
Sell9.00+0.78%6.00MaintainAug 25, 2025
TD Cowen
Buy16.00+79.17%12.00MaintainAug 08, 2025

Ginkgo Bioworks Holdings Earnings Call Summary for Q1/2026

  • Q1 2026 revenue plunged 49% YoY to $19M, driven by biosecurity unit divestiture and weak core service revenues.
  • Net loss narrowed 8% to $76M; adjusted EBITDA improved 5% to negative $42M; cash burn reduced 17% to $48M.
  • Company holds $373M cash with zero bank debt; reaffirmed 2026 cash burn guidance of $125M-$150M.
  • Restructuring efforts cut operating expenses significantly; strategic focus shifts to autonomous lab development and core services.
  • Stock fell 1.29% to $10.36 in aftermarket despite 24% YTD gain; market cap stands at $606M.
Last Updated: 2026-05-07, 09:02 p/m
Read Full Transcript

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-1.42 / -0.07
Revenue / Forecast
33.4M / 119.68M
EPS Revisions
Last 90 days

DNA Income Statement

Compare DNA to Peers and Sector

Metrics to compare
DNA
Peers
Sector
Relationship
P/E Ratio
−1.9x−5.8x−0.5x
PEG Ratio
−0.04−0.140.00
Price/Book
1.1x1.4x2.6x
Price / LTM Sales
3.4x6.0x3.2x
Upside (Analyst Target)
−10.7%125.6%47.8%
Fair Value Upside
Unlock−2.8%5.9%Unlock

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
12.87M22.11%114.94M
Other Institutional Investors
23.23M39.90%207.40M
Public Companies & Retail Investors
22.11M37.99%197.45M
Total
58.21M100.00%519.79M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Viking Global Investors LP6.15%3,577,12831,944
BlackRock, Inc.6.14%3,573,36931,910

People Also Watch

0.907
QSI
-7.55%
32.32
BEAM
+2.70%
5.490
RXT
+55.97%
2.060
SABR
-0.48%

FAQ

What Is the Ginkgo Bioworks (DNA) Stock Price Today?

The Ginkgo Bioworks stock price today is 8.930 USD.

What Stock Exchange Does Ginkgo Bioworks Trade On?

Ginkgo Bioworks is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Ginkgo Bioworks?

The stock symbol for Ginkgo Bioworks is "DNA."

What Is the Ginkgo Bioworks Market Cap?

As of today, Ginkgo Bioworks market cap is 581.660M USD.

What Is Ginkgo Bioworks's Earnings Per Share (TTM)?

The Ginkgo Bioworks EPS (TTM) is -5.360.

From a Technical Analysis Perspective, Is DNA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Ginkgo Bioworks Stock Split?

Ginkgo Bioworks has split 1 times.

How Many Employees Does Ginkgo Bioworks Have?

Ginkgo Bioworks has 485 employees.

What is the current trading status of Ginkgo Bioworks (DNA)?

As of May 09, 2026, Ginkgo Bioworks (DNA) is trading at a price of 8.930 USD, with a previous close of 10.320 USD. The stock has fluctuated within a day range of 8.350 USD to 9.544 USD, while its 52-week range spans from 5.370 USD to 17.580 USD.

What Is Ginkgo Bioworks (DNA) Price Target According to Analysts?

The average 12-month price target for Ginkgo Bioworks is 8.500 USD, with a high estimate of 12 USD and a low estimate of 5 USD. 1 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an -4.82% Downside potential.

What Is the DNA Premarket Price?

DNA's last pre-market stock price is 8.820 USD. The pre-market share volume is 37,970.000, and the stock has decreased by -1.500, or -14.530%.

What Is the DNA After Hours Price?

DNA's last after hours stock price is 9.250 USD, the stock has decreased by 0.320, or 3.580%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.